Atrio Search’s Post

Atrio Search reposted this

View profile for Dylon Allsopp, graphic

Managing Director - CDMO Global Headhunter

𝗞𝗲𝘆 𝗖𝗠𝗗𝗢 𝗨𝗽𝗱𝗮𝘁𝗲𝘀 📍 Chime Biologics aims to significantly scale up its manufacturing operations in China and expand into the Asia-Pacific markets. The increase in drug substance capacity from 28,000L to approximately 100,000L will enable the company to manufacture 15 to 20 commercial products 📍 Asymchem Group has inaugurated its new European development and pilot manufacturing site at Discovery Park in Sandwich, Kent, UK (Formerly owned by Pfizer) 📍 Samsung Biologics announced its membership in the Pharmaceutical Supply Chain Initiative (PSCI) as a Supplier Partner which is the first Korean CDMO to do so. 📍 QHP Capital announced the appointment of Owen Murray as the new Chief Executive Officer for the recently combined entities of Bend Bioscience, CoreRx, Inc., and Societal™ CDMO 📍 US Specialty Formulations LLC is expanding its Lehigh Valley biopharma facility in Allentown with a $15 million investment to introduce new clean room suites and state-of-the-art automated packaging and product inspection equipment 📍 Singota Solutions announced the expansion of its European services with the opening of a new storage facility in Rovello Porro, Italy. This new facility, certified by the Italian Medicines Agency (AIFA), offers -40°C and -20°C pallet storage and enhances Singota’s existing capabilities in aseptic manufacturing and cold chain pharmaceutical storage 📍 Phosphorex has received a strategic investment from NOF AMERICA CORPORATION. The Ampersand Capital Partners backed investment will accelerate Phosphorex’s cGMP capabilities and strengthen its global position in nanoparticle-based drug delivery #CDMO #ContractDevelopment #ContractManufacturing

  • No alternative text description for this image

Thanks for the shout out!! We're very excited about our announcement with NOF AMERICA CORPORATION!

Like
Reply

Exciting times! Thank you so much for sharing out our expansion news!

See more comments

To view or add a comment, sign in

Explore topics